225 results on '"Trefzer, U."'
Search Results
2. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
3. Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
4. Hybrid Cell Vaccination in Cancer Immunotherapy : Recruitment and Activation of T Cell Help for Induction of Anti Tumour Cytotoxic T Cells
5. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
6. Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study
7. Blisters—an unusual effect during radiotherapy
8. BOLT - eine randomisierte, doppelblinde Studie mit Sonidegib (LDE225) bei Patienten mit lokal fortgeschrittenem oder metastasiertem Basalzellkarzinom: FV4
9. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells: ID 018
10. Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
11. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study
12. Das Merkelzellkarzinom-Register der ADO - die erste Auswertung: FV24
13. Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma: FV5
14. Multicenter, Prospective Follow-Up Study of Melanoma Patients in Germany: Results of an Interim Analysis 2 years after Initial Diagnosis: FC-030
15. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
16. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions
17. FV5 Sorafenib and pegylated interferon alpha in advanced metastatic melanoma: a multicenter phase II DeCOG trial
18. Monitoring of circulating tumor cells in a patient with synchronous metastatic melanoma and colon carcinoma
19. Ultra-late recurrence of malignant melanoma after a disease-free interval of 41 years
20. Hypertrichosis in three patients treated with interferon-α2
21. Evaluierung des Tumormarkers MIA in der Primärdiagnostik und Nachsorge von Stadium I und II Melanompatienten: FV38
22. Cancer Stem Cells in Melanoma: FV3
23. MC polyomavirus is frequently present in Merkel cell carcinoma of European patients: FV2
24. IL-7 mRNA is not overexpressed in mycosis fungoides and pleomorphic T-cell lymphoma and is unlikely to be an autocrine growth factor in vivo
25. Standard palliative care in Kombination mit Polychemotherapie (DVP-Schema) versus standard palliative care allein als second-line Therapie des malignen Melanoms im Stadium IV (ADO-Studie MM-PAL 8): V11
26. Expression des humanen endogenen Retrovirus HERV-K in humanen Melanomen und Evidenzfür immunsuppressive Eigenschaften seines transmembranen Hüllproteins: P21/25
27. Wertigkeit des Melanom-Tumormarkers MIA in der Nachsorge von Stadium I und II Melanompatienten: P21/26
28. Vitiligo-like depigmentation as a presenting sign of metastatic melanoma
29. Grand mal seizure induced by interferon-α-2b
30. Parathyroid hormone-related protein-induced hypercalcaemia in metastatic melanoma
31. Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma
32. Pigmented vulvar lesions
33. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
34. Cytokines: interleukin and interferon therapy in dermatology
35. Cytokine therapy in dermatology
36. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
37. Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study.
38. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
39. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial
40. Expression and functional activity of glycophospholipid-anchored intercellular adhesion molecule-1 (ICAM-1) in a human keratinocyte tumor cell line
41. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
42. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
43. PCN140 - Change in Fatigue and Correlations with Clinical Outcome in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib in the Bolt Study
44. LBA33 - Randomized, Double-Blind Study of Sonidegib (Lde225) in Patients (Pts) with Advanced Basal Cell Carcinoma (Bcc)
45. 1125P - Patient-Reported Quality of Life (Qol) with Sonidegib (Lde225) in Advanced Basal Cell Carcinoma (Bcc)
46. Treatment Planning for Merkel Cell Carcinoma Based on the Relapse Pattern
47. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
48. Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin.
49. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
50. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.